TradingKey – Merck stock surged after its personalized mRNA cancer therapy met both Phase 3 melanoma endpoints. Strong Q2 sales and pipeline growth support MRK’s outlook.
All rights reserved © HK MoneyClub. 聲明：網站為媒體資訊教育平台，任何內容不構成買賣建議。投資存在風險，作任何決定需自行承擔結果。本網站由Talentswire Company Limited全權擁有。
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.